GG/TA-Zn复合液凝通过炎症调节和血管骨协同作用来增强糖尿病骨缺陷的愈合效果
Xiaohui Tang1, Bo Liu1, Haishui Jiang1
1College of Chemical Engineering, Xinjiang Normal University, 102 Xinyi Road, Urumqi, 830054, PR China.
International journal of biological macromolecules
|March 10, 2026
概括
这项研究介绍了一种用于糖尿病骨修复的新型凝乳/酸-水凝. 复合水凝有效减少炎症,通过调节细胞微环境,促进骨再生.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 组织工程是组织工程.
背景情况:
- 糖尿病骨缺陷由于炎症,氧化应激和骨代谢不良而带来挑战.
- 现有的治疗方法在解决糖尿病骨损失的复杂病理生理学方面是有限的.
研究的目的:
- 开发一种多功能凝乳/酸- (GG/TA-Zn) 复合水凝,用于糖尿病患者的骨缺陷修复.
- 在实验室中研究水凝的抗炎,抗氧化,益血管和骨质性质.
主要方法:
- 制造具有受控离子释放的GG/TA-Zn复合水凝.
- 在体外评估抗氧化能力 (ROS清除) 和对巨细胞的免疫调节作用 (M1到M2极化).
- 使用内皮细胞和骨髓介质干细胞 (BMSCs) 评估亲血管和骨质潜能.
主要成果:
- GG/TA-Zn水凝显示出显著的ROS清理和调节的巨细胞极化,减少促炎细胞因子 (IL-1β,IL-6,TNF-α) 和增加抗炎介质 (IL-4,IL-10).
- 通过刺激内皮细胞增殖和迁移观察到增强的血管生成.
- 促进了BMSC的骨质生成分化,由增加的ALP活性,矿化结节的形成和上调的骨质生成标志物 (Runx2,OCN,OPN) 证明.
结论:
- 多功能GG/TA-Zn水凝通过调节微环境和促进协调组织再生,显示出它是糖尿病骨修复的体外平台.
- 需要进一步的体内研究来评估其对糖尿病相关骨缺陷的翻译潜力.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...